138 related articles for article (PubMed ID: 24942978)
1. Cell-based biological evaluation of a new bisamide FMS kinase inhibitor possessing pyrrolo[3,2-c]pyridine scaffold.
El-Gamal MI; Abdel-Maksoud MS; El-Din MM; Yoo KH; Baek D; Oh CH
Arch Pharm (Weinheim); 2014 Sep; 347(9):635-41. PubMed ID: 24942978
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies.
El-Gamal MI; Oh CH
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1160-1166. PubMed ID: 30070930
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a new potent bisamide FMS kinase inhibitor.
El-Gamal MI; Jung MH; Oh CH
Bioorg Med Chem Lett; 2010 Jun; 20(11):3216-8. PubMed ID: 20457522
[TBL] [Abstract][Full Text] [Related]
4. A new series of diarylamides possessing quinoline nucleus: Synthesis, in vitro anticancer activities, and kinase inhibitory effect.
El-Gamal MI; Khan MA; Abdel-Maksoud MS; Gamal El-Din MM; Oh CH
Eur J Med Chem; 2014 Nov; 87():484-92. PubMed ID: 25282271
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of new diarylamides with pyrimidinyl pyridine scaffold and evaluation of their anti-proliferative effect on cancer cell lines.
Abdelazem AZ; Al-Sanea MM; Park HM; Lee SH
Bioorg Med Chem Lett; 2016 Feb; 26(4):1301-4. PubMed ID: 26786696
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
8. New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.
Koh EJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Hong JH; Lee SG; Yoo KH
Eur J Med Chem; 2013; 70():10-21. PubMed ID: 24128410
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
Eur J Med Chem; 2016 Aug; 119():122-31. PubMed ID: 27155467
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
Illig CR; Manthey CL; Meegalla SK; Wall MJ; Chen J; Wilson KJ; DesJarlais RL; Ballentine SK; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Donatelli RR; Yurkow E; Zhou Z; Player MR; Tomczuk BE
Bioorg Med Chem Lett; 2013 Dec; 23(23):6363-9. PubMed ID: 24138939
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
Jung MH; El-Gamal MI; Abdel-Maksoud MS; Sim T; Yoo KH; Oh CH
Bioorg Med Chem Lett; 2012 Jul; 22(13):4362-7. PubMed ID: 22647720
[TBL] [Abstract][Full Text] [Related]
13. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
El-Gamal MI; Jung MH; Lee WS; Sim T; Yoo KH; Oh CH
Eur J Med Chem; 2011 Aug; 46(8):3218-26. PubMed ID: 21592628
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
El-Deeb IM; Lee SH
Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
[TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor.
Gabr MT; El-Gohary NS; El-Bendary ER; El-Kerdawy MM
J Enzyme Inhib Med Chem; 2015 Feb; 30(1):160-5. PubMed ID: 24601650
[TBL] [Abstract][Full Text] [Related]
20. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
Wilson KJ; Illig CR; Chen J; Wall MJ; Ballentine SK; DesJarlais RL; Chen Y; Schubert C; Donatelli R; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2010 Jul; 20(13):3925-9. PubMed ID: 20570147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
